Evidence map›Paper›PMID 36704579›Full record

ArticleFrontiers in genome editing2022

Are null segregants new combinations of heritable material and should they be regulated?

Jack A Heinemann, Katrin Clark, Tessa C Hiscox, Andrew W McCabe, Sarah Z Agapito-Tenfen

Abstract read
In one paragraph

Article in Frontiers in genome editing, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jack A HeinemannCentre for Integrated Research in Biosafety and School of Biological Sciences, University of Canterbury, Christchurch, New Zealand.
Katrin ClarkCentre for Integrated Research in Biosafety and School of Biological Sciences, University of Canterbury, Christchurch, New Zealand.
Tessa C HiscoxCentre for Integrated Research in Biosafety and School of Biological Sciences, University of Canterbury, Christchurch, New Zealand.
Andrew W McCabeCentre for Integrated Research in Biosafety and School of Biological Sciences, University of Canterbury, Christchurch, New Zealand.
Sarah Z Agapito-TenfenClimate and Environment Division, NORCE Norwegian Research Centre AS, Tromsø, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Through genome editing and other techniques of gene technology, it is possible to create a class of organism called null segregants. These genetically modified organisms (GMOs) are products of gene technology but are argued to have no lingering vestige of the technology after the segregation of chromosomes or deletion of insertions. From that viewpoint regulations are redundant because any unique potential for the use of gene technology to cause harm has also been removed. We tackle this question of international interest by reviewing the early history of the purpose of gene technology regulation. The active ingredients of techniques used for guided mutagenesis, e.g., site-directed nucleases, such as CRISPR/Cas, are promoted for having a lower potential per reaction to create a hazard. However, others see this as a desirable industrial property of the reagents that will lead to genome editing being used more and nullifying the promised hazard mitigation. The contest between views revolves around whether regulations could alter the risks in the responsible use of gene technology. We conclude that gene technology, even when used to make null segregants, has characteristics that make regulation a reasonable option for mitigating potential harm. Those characteristics are that it allows people to create more harm faster, even if it creates benefits as well; the potential for harm increases with increased use of the technique, but safety does not; and regulations can control harm scaling.

Indexed as

gene technologynull/negative segregantsregulationrisk assessmentscalesustainable development goal 12sustainable development goal 13

Identifiers

PMID36704579
PMCPMC9871356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.